The dollars and sense of chronic hepatitis C infection management

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 26, Issue 3, 2015, Pages 119-121

  Laupland, Kevin B ^a,b   Valiquette, Louis ^c  

^a ROYAL INLAND HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SOFOSBUVIR;

ARTICLE; CANADA; GENOTYPE; HEPATITIS C; HUMAN;

EID: 84936873952     PISSN: 17129532     EISSN: 19181493     Source Type: Journal    
DOI: 10.1155/2015/301439     Document Type: Article

References (31)

1. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29:19-34.
2. Hull M, Shafran S, Tseng A, Giguere P, Klein MB, Cooper C. CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults. Can J Infect Dis Med Microbiol 2014;25:311-20.
3. Myers RP, Krajden M, Bilodeau M, et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol 2014;28:243-50.
4. Kwong JC, Ratnasingham S, Campitelli MA, et al. The impact of infection on population health: Results of the Ontario burden of infectious diseases study. PLoS One 2012;7:e44103.
5. Klein MB, Rollet-Kurhajec KC, Moodie EE, et al. Mortality in HIVhepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). AIDS 2014;28:1957-65.
6. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011;6:478-82.
7. Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014;20:9270-80.
8. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011;364:2429-38.
9. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015;62(1S):S87-S99.
10. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8.
11. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Int Med 2004;140:346-55.
12. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
13. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
14. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014;146:736-43, e1.
15. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
16. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatmentnaive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014;383:515-23.
17. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection. Gastroenterology 2014;147:359-65 e1.
18. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
19. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-14.
20. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-92.
21. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82.
22. Price of AbbVie Holkira Pak™ hepatitis C treatment in Canada. Hepatitis C Education and Prevention Society. (Accessed May 4, 2015).
23. Updates to Canadian sofosfovir pricing and CADTH queuing schedule. Hepatitis C Education and Prevention Society. (Accessed May 4, 2015).
24. Hoofnagle JH, Sherker AH. Therapy for hepatitis C - The costs of success. N Engl J Med 2014;370:1552-3.
25. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
26. With hep C, no province is an island. The Globe and Mail. (Accessed May 5, 2015).
27. Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: Prospective cohort study. BMJ 2009;338:b1649.
28. El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ 2005;6:159-65.
29. Golubchuk family drops end-of-life lawsuit against Winnipeg health authority. Canadian Medicine. (Accessed May 5, 2015).
30. Wong WW, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-21.
31. Myers RP, Cooper C, Sherman M, et al. Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: Final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol 2011;25:503-10.